Peptide record

TPDB91328

Cecropin B Antibacterial Anticancer Antifungal Antiparasitic Toxicity modified_plain modified
35 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91328
Cecropin B
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb ToxinPred 3.0
modified_plain
Yes
A 35-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KWKIFKKIEKVGRNIRNGIIKAGPAVAVLGEAKAL-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
35 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
Chinese oak silk moth Activity
Evidence Records 12 records
Evidence 1 Activity

Activity

IC50
IC50=161.76 µg/ml
Anticancer
161.76 µg/mL

Target

Bladder Cancer
486P
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=184.81 µg/ml
Anticancer
184.81 µg/mL

Target

Bladder Cancer
RT4
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 3 Activity

Activity

IC50
IC50=115.12 µg/ml
Anticancer
115.12 µg/mL

Target

Bladder Cancer
647V
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 4 Activity

Activity

IC50
IC50=97.93 µg/ml
Anticancer
97.93 µg/mL

Target

Bladder Cancer
J82
Bladder

Assay & Model

WST-1 assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 5 Activity

Activity

IC50
IC50=87.47 µg/ml
Anticancer
87.47 µg/mL

Target

Bladder Cancer
486P
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 6 Activity

Activity

IC50
IC50=92.9 µg/ml
Anticancer
92.9 µg/mL

Target

Bladder Cancer
RT4
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 7 Activity

Activity

IC50
IC50=61.86 µg/ml
Anticancer
61.86 µg/mL

Target

Bladder Cancer
647V
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 8 Activity

Activity

IC50
IC50=77.51 µg/ml
Anticancer
77.51 µg/mL

Target

Bladder Cancer
J82
Bladder

Assay & Model

Cell Viability assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 9 Activity

Activity

IC50
IC50=232.4 µg/ml
Anticancer
232.4 µg/mL

Target

Bladder Cancer
486P
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 10 Activity

Activity

IC50
IC50=240.4 µg/ml
Anticancer
240.4 µg/mL

Target

Bladder Cancer
RT4
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 11 Activity

Activity

IC50
IC50=181.1 µg/ml
Anticancer
181.1 µg/mL

Target

Bladder Cancer
647V
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 12 Activity

Activity

Cytotoxicity
Cytotoxicity=196.3 µg/ml
Anticancer

Target

Bladder Cancer
J82
Bladder

Assay & Model

LDH leakage assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008